Selective PDE4B Small-Molecule Inhibitors for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PDE4 inhibitors exhibit significant side effects such as nausea and vomiting due to their lack of subtype selectivity, particularly affecting PDE4D, while PDE4B is associated with inflammatory responses and has fewer side effects, limiting their clinical application.
Innovation Solution
Development of a small molecule compound with selective PDE4B inhibitory activity, targeting the regulatory sequence difference between PDE4B and PDE4D to achieve subtype selectivity, thereby reducing side effects and maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PDE4 inhibitors are used to treat inflammatory diseases, then therapeutic efficacy is achieved, but side effects such as nausea and vomiting increase
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures (formula I compounds) that target the catalytic domain of PDE4B with high selectivity. The inhibitors contain specific functional groups and spatial arrangements that preferentially bind to PDE4B over other PDE4 subtypes, thereby achieving therapeutic efficacy in inflammatory diseases while minimizing side effects associated with non-selective inhibition.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular parameters of PDE4 inhibitors to achieve subtype selectivity. This involves adjusting the chemical structure, binding affinity, and pharmacokinetic parameters of the inhibitors to specifically target PDE4B, thereby changing the overall effect profile from non-selective to selective inhibition, which reduces side effects while maintaining therapeutic benefit.
2Object-affected harmful factors
If PDE4B selective inhibitors are designed to reduce side effects, then safety improves, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the PDE4 inhibitor development into distinct functional components: a catalytic domain binding moiety and a regulatory sequence binding moiety. This segmentation allows independent optimization of each component to achieve selectivity for PDE4B, thereby reducing side effects while managing development complexity through modular design.
Solution Approach 2:
The patent uses an intermediary approach by identifying and utilizing the regulatory sequence as a mediating element between the inhibitor and the PDE4B enzyme. The regulatory sequence acts as a selective binding site that distinguishes PDE4B from other subtypes, enabling the development of selective inhibitors without requiring complete redesign of the entire inhibitor molecule, thus reducing development complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound achieves selective inhibition of PDE4B, reducing side effects and enhancing the clinical applicability of PDE4 inhibitors for treating conditions like COPD and cancer with improved pharmacokinetics.
Implementation Method 1
PDE4 inhibitors play an anti-inflammatory role mainly by inhibiting the hydrolysis function of PDE4 so as to increase the cAMP level in vivo
Data Source
AI summary
Disclosed are a compound as represented by formula I; a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same; and the use thereof as a PDE4B inhibitor in the preparation of a drug for the treatment of related diseases. Each group as shown in formula (I) is as defined in the description.